Virtu Financial’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Virtu Financial’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,428	Closed	-$977K	–	2195
2023 Q2	$977K	Buy	+25,428	New	+$653K	0.07%	212
2020 Q3	–	Sell	-3,989	Closed	-$46K	–	1667
2020 Q2	$46K	Buy	+3,989	New	+$55K	0.01%	1015
2019 Q4	$75K	Buy	12,681 +5,901	+87%	+$32.1K	0.01%	1139
2019 Q3	$36K	Buy	6,780 +4,755	+235%	+$31.6K	﹤0.01%	1238
2019 Q2	$16K	Buy	+2,025	New	+$30.8K	﹤0.01%	1366
2019 Q1	–	Sell	-2,847	Closed	-$38K	–	1991
2018 Q4	$38K	Buy	+2,847	New	+$56.9K	﹤0.01%	1305

Virtu Financial's KDNY Position: Q3 2023 in Review

Virtu Financial sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 25,428 shares — an estimated $977K sold.

Virtu Financial first reported a position in KDNY in Q4 2018 and held it in 6 quarters. The position peaked at $977K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Virtu Financial reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Virtu Financial sold 25,428 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $977K.
Virtu Financial first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2018 and held it in 6 quarters.
Virtu Financial's Chinook Therapeutics, Inc. Common Stock position peaked at $977K in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Virtu Financial's 13F filing for Q3 2023, filed 15 Nov 2023.